SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive, meme-like volatility and parabolic price action as retail traders and institutional flows surge ahead of the company's upcoming inclusion in the Nasdaq-100. Community sentiment is deeply polarized, with bulls chasing momentum fueled by AI-driven memory demand and rumors of a stock split, while skeptics warn of an overextended bubble nearing a potential distribution top.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a buyout or aggressive turnaround, fueled by persistent short interest and frustration over the board's delay in naming a permanent CEO. While some market participants see deep value in the brand's international expansion and high dividend yield, others remain skeptical, pointing to lackluster domestic performance and operational challenges.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and bearish sentiment as investors weigh concerns over massive AI-related capital expenditures, high debt levels, and recent layoffs against its ambitious cloud infrastructure expansion. While the community is deeply divided between long-term bulls highlighting substantial revenue backlogs and AI-driven growth potential versus skeptics wary of slowing enterprise software demand and valuation risks, the stock continues to face heavy selling pressure.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to its recent award of over $4 million in U.S. government contracts, which investors view as a pivotal validation of its semiconductor and quantum materials technology. The community is actively debating the company's long-term potential to scale its proprietary platform while closely monitoring its ability to move from research-focused government projects to high-volume commercial manufacturing partnerships.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors react to bullish analyst upgrades, a major $151 billion defense contract, and strategic partnerships involving AI-driven network infrastructure and data centers. The community is actively discussing its long-term potential as a key player in the 6G and AI-RAN space, with many comparing its current trajectory to other optical powerhouses while debating the impact of increased institutional buying and recent technical breakouts.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and bullish sentiment driven by investor anticipation of a potential gamma squeeze as market makers move to hedge against heavy call option activity. The community is actively discussing the stock's role in the AI-driven optical interconnect sector, with many highlighting its potential as a critical, high-margin supplier within the broader data center infrastructure space.

Maulcoin

Maulcoin is generating significant momentum as a community-driven project that is rallying its 'Mauler' base to push toward milestones like a million-dollar market cap. Participants are actively engaging on social platforms to boost visibility and drive growth, focusing on long-term holding and collective action to establish the token as a durable player in the meme coin space.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the company's electro-optic polymer technology as a scalable, energy-efficient solution for AI data centers. The community is actively debating the company's transition from R&D to foundry-integrated manufacturing, with recent industry partnerships and speculation regarding potential major acquisition interest driving significant price volatility.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest positive late-stage trial results for their pancreatic cancer drug, daraxonrasib, which significantly improved patient survival rates compared to standard chemotherapy. The community is heavily focused on the drug's practice-changing clinical outcomes and the potential for the company to emerge as a dominant force in targeted oncology, fueling intense speculation regarding its long-term market valuation and buyout prospects.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a meme-driven cultural asset that traces its roots back to a 2011 BitcoinTalk forum joke, with community members emphasizing its long history and parody status compared to newer meme coins. Investors are actively discussing whale accumulation and a 'billion-dollar' narrative, fueled by community efforts to establish the project as an enduring, ironic alternative to traditional crypto.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD

State of Alaska Department of Revenue decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent...

Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD

Greenup Street Wealth Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the...

Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD

Sumitomo Mitsui Trust Group Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,269,117 shares of the biopha...

Robeco Institutional Asset Management B.V. Sells 108,349 Shares of Gilead Sciences, Inc. $GILD

Robeco Institutional Asset Management B.V. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,693,602 shares...

Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD

Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3,763.8% during the 4th quarter, according to the company in its most...

Pharmaceutical Stocks To Research - April 11th

Eli Lilly and Company, Abbott Laboratories, AbbVie, Pfizer, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD

Ritholtz Wealth Management raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,318 shares of the biopharmaceutical company's stock after buy...

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200

Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00

Morgan Stanley increased their price objective on Gilead Sciences from $171.00 to $175.00 and gave the company an "overweight" rating in a report on Friday...

<ul class="summary-bullets"><li>The firm said MGNX is uniquely positioned in the emerging Antibody-Drug Conjugate therapy space.</li><li>B. Riley said Gilead’s $5 billion acquisition of Tubulus earlier this week prompted it to develop its own valuation models for ADC firms.</li><li>On Wednesday, MGNX said the U.S. FDA has lifted the partial clinical hold on its Phase 2 trial of a drug to treat cancer.</li></ul>Shares of MacroGenics (MGNX) surged around 10% on Friday, with the stock hitting its highest levels since November 2024. This comes after a bullish analyst call highlighted significant upside potential, with the firm projecting gains of up to 140% from current levels.On Friday, B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.<h2 class="st-heading-2">B. Riley Upgrades Stock After Gilead Tubulus Deal</h2>The brokerage said that after Gilead Sciences’ (GILD) $5 billion deal to acquire Tubulus earlier this week, it developed its own valuation model for next-generation Antibody-Drug Conjugate (ADC) companies and believes MGNX is uniquely positioned in the emerging “ADAM9 TOPO1i ADC space.”ADC is a cancer treatment that combines targeted therapy and chemotherapy.On Tuesday, Gilead Sciences (GILD) <a href="https://stocktwits.com/news-articles/markets/equity/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc">entered</a> into a definitive agreement to acquire Tubulis GmbH, a German clinical-stage biotechnology company. Gilead will pay $3.15 billion upfront, and up to $1.85 billion in additional milestone payments.The deal strengthens Gilead’s ADC pipeline by adding Tubulis’ assets, including TUB-040, a drug in development for ovarian and non-small cell lung cancers.<h2 class="st-heading-2">FDA Lifts Partial Clinical Hold On Ovarian Cancer Trial</h2>On Wednesday, MGNX said the U.S. FDA had lifted the partial clinical hold on its Phase 2 LINNET study of Lorigerlimab, a cancer drug. The trial is testing the drug in patients with certain advanced ovarian and gynecologic cancers who have already received prior treatments.So far, 41 patients have been treated in the study, with over 300 patients dosed across earlier trials.Existing patients were allowed to continue treatment during the hold, and the study will now resume enrolling new patients under an updated protocol with added safety measures.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MGNX">MGNX</a> on Stocktwits flipped to ‘bullish’ from ‘bearish’, amid high message volumes.One user said the stock’s valuation was “too low.”<stembedurl>https://stocktwits.com/perchedcats/message/649223850</stembedurl>Year-to-date, the stock has surged around 133%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside

B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.

Equity

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.90	--	--	N/A
Q4 '25	$1.81	$1.86	2.76%	BEAT
Q3 '25	$2.13	$2.47	15.85%	BEAT
Q2 '25	$1.96	$2.01	2.55%	BEAT
Q1 '25	$1.78	$1.81	1.66%	BEAT

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest GILD News

GILDGilead Sciences, Inc.